W-Net for Whole-Body Bone Lesion Detection on $$^{68}$$ Ga-Pentixafor PET/CT Imaging of Multiple Myeloma Patients

2017 ◽  
pp. 23-30 ◽  
Author(s):  
Lina Xu ◽  
Giles Tetteh ◽  
Mona Mustafa ◽  
Jana Lipkova ◽  
Yu Zhao ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Lesion ◽  
Ct Imaging ◽  
Lesion Detection ◽  
Whole Body ◽  
Pet Ct ◽  
Body Bone

scholarly journals Automated Whole-Body Bone Lesion Detection for Multiple Myeloma on 68Ga-Pentixafor PET/CT Imaging Using Deep Learning Methods

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Lina Xu ◽  
Giles Tetteh ◽  
Jana Lipkova ◽  
Yu Zhao ◽  
Hongwei Li ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Deep Learning ◽  
Bone Lesion ◽  
Lesion Detection ◽  
Feature Representation ◽  
Whole Body ◽  
Support Vector ◽  
Bone Lesions ◽  
Learning Methods ◽  
Pet Ct

The identification of bone lesions is crucial in the diagnostic assessment of multiple myeloma (MM). 68Ga-Pentixafor PET/CT can capture the abnormal molecular expression of CXCR-4 in addition to anatomical changes. However, whole-body detection of dozens of lesions on hybrid imaging is tedious and error prone. It is even more difficult to identify lesions with a large heterogeneity. This study employed deep learning methods to automatically combine characteristics of PET and CT for whole-body MM bone lesion detection in a 3D manner. Two convolutional neural networks (CNNs), V-Net and W-Net, were adopted to segment and detect the lesions. The feasibility of deep learning for lesion detection on 68Ga-Pentixafor PET/CT was first verified on digital phantoms generated using realistic PET simulation methods. Then the proposed methods were evaluated on real 68Ga-Pentixafor PET/CT scans of MM patients. The preliminary results showed that deep learning method can leverage multimodal information for spatial feature representation, and W-Net obtained the best result for segmentation and lesion detection. It also outperformed traditional machine learning methods such as random forest classifier (RF), k-Nearest Neighbors (k-NN), and support vector machine (SVM). The proof-of-concept study encourages further development of deep learning approach for MM lesion detection in population study.

scholarly journals Diagnostic Value of Whole-Body MRI Short Protocols in Bone Lesion Detection in Multiple Myeloma Patients

Diagnostics ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1053
Author(s):  
Davide Ippolito ◽  
Teresa Giandola ◽  
Cesare Maino ◽  
Davide Gandola ◽  
Maria Ragusi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow Involvement ◽  
Bone Lesion ◽  
Diagnostic Value ◽  
Lesion Detection ◽  
Lower Limbs ◽  
Whole Body ◽  
Bone Lesions ◽  
Whole Body Mri ◽  
Mri Protocol

The aim of the study is to evaluate the effectiveness of short whole-body magnetic resonance imaging (WBMRI) protocols for the overall assessment of bone marrow involvement in patients with multiple myeloma (MM), in comparison with standard whole-body MRI protocol. Patients with biopsy-proven MM, who underwent a WBMRI with full-body coverage (from vertex to feet) were retrospectively enrolled. WBMRI images were independently evaluated by two expert radiologists, in terms of infiltration patterns (normal, focal, diffuse, and combined), according to location (the whole skeleton was divided into six anatomic districts: skull, spine, sternum and ribs, upper limbs, pelvis and proximal two-thirds of the femur, remaining parts of lower limbs) and lytic lesions number (<5, 5–20, and >20). The majority of patients showed focal and combined infiltration patterns with bone lesions predominantly distributed in the spine and pelvis. As skull and lower limbs are less frequently involved by focal bone lesions, excluding them from the standard MRI protocol allows to obtain a shorter protocol, maintaining a good diagnostic value.

A statistically optimized regional thresholding method (SORT) for bone lesion detection in 18F-NaF PET/CT imaging

2018 ◽  
Vol 63 (22) ◽  
pp. 225018 ◽  
Author(s):  
Timothy Perk ◽  
Song Chen ◽  
Stephanie Harmon ◽  
Christie Lin ◽  
Tyler Bradshaw ◽  
...  
Keyword(s):  
Bone Lesion ◽  
Ct Imaging ◽  
Lesion Detection ◽  
Thresholding Method ◽  
Pet Ct

scholarly journals A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma

2017 ◽  
Vol 2017 ◽  
pp. 1-7
Author(s):  
Nadia Withofs ◽  
François Cousin ◽  
Bernard De Prijck ◽  
Christophe Bonnet ◽  
Roland Hustinx ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Fdg Pet ◽  
Low Dose ◽  
Bone Lesion ◽  
Bone Destruction ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Low Dose Ct ◽  
Pet Ct ◽  
Fdg Pet Ct

An observational study was set up to assess the feasibility of [F18]FPRGD2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [F18]NaF/[F18]FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of [F18]FPRGD2. The obtained images were compared with results of low dose CT and already available results of a combined [F18]NaF/[F18]FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [F18]FPRGD2 PET/CT compared to low dose CT (98%) or [F18]NaF/[F18]FDG PET/CT (70%) and all FLs detected with [F18]FPRGD2 PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [F18]FPRGD2 positive lesions were seen than [F18]NaF/[F18]FDG positive lesions. This study suggests that [F18]FPRGD2 PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with [F18]FPRGD2 uptake were already detected with CT alone.

scholarly journals Comparison Between Whole-Body MRI and PET/CT in Pediatric Oncology

2017 ◽  
Vol 17 (1) ◽  
pp. 15-17
Author(s):  
Anastasija Trofimovica ◽  
Ilze Apine
Keyword(s):  
Soft Tissue ◽  
Lymph Nodes ◽  
Radiation Exposure ◽  
Bone Lesion ◽  
Ct Imaging ◽  
Whole Body ◽  
Mri Imaging ◽  
Whole Body Mri ◽  
Soft Tissue Lesions ◽  
Pet Ct

Summary Introduction. Positron emission tomography/computer tomography (PET/CT) is one of the main imaging tests for solid tumor and metastases diagnostic nowadays. However, PET/CT scanning is related to the risk of ionizing radiation exposure, which is especially harmful for children health. Whole-body MRI (WB-MRI) allows exact evaluation of malignant tumor without the radiation exposure. Aim of the Study.To compare and evaluate informativity of WB-MRI and PET/CT imaging methods for detection of metastases in children with malignant disease, being treated at Children’s Clinical University Hospital, Riga, Latvia. The gained data were also compared to the world data published before. Material and methods. This retrospective study included all patients in whom both PET/CT and WB-MRI imaging examinations were performed between July 2016 and February 2017 in Latvia. Inclusion criteria were: age under 18 years, histological confirmation of a malignant disease. The study included 10 patients (7 males, 3 females, mean age 11 years 7 months). Two patients underwent both examinations 3 times, resulting in a total of 14 cases. Results. There were identified three types of tumor: Hodgkin lymphoma (n = 12), non-Hodgkin lymphoma (n = 1), rhabdomyosarcoma (n = 1). PET/CT mean radiation exposure was 263,2 [95% CI: 202.27 - 324.12] mGy.cm, mean radiotracer dosage was 143,5 [95% CI: 114. - 172.52] MBq. There were identified 34 lesions: 24 (70%) lymph nodes, 5 (15%) bone lesions, 5 (15%) soft tissue lesions. 21 malignant lesions were detected by PET/CT. 27 lesions were found by WB-MRI. Out of 34 lesions, eighteen were identified by both imaging methods. Both examinations found absence of residual disease in 2 cases. Eleven lesions were detected by WB-MRI (7 lymph nodes, 1 bone lesion and 3 soft tissue lesions) that were not identified by PET/ CT. 5 lesions could not be identified by WB-MRI (2 lymph nodes, 1 bone lesion and 2 soft tissue lesions) that were detected by PET/CT imaging method. Conclusions. WB-MRI examination should be used before and in addition to PET/CT imagining in children with oncological disease. PET/CT examination results interpretation should be done based on WB-MRI imaging results. WB-MRI could not completely replace PET/CT imaging.

Overview and recent advances in PET/CT imaging in Lymphoma and Multiple Myeloma

2021 ◽  
pp. 109793
Author(s):  
Zanoni Lucia ◽  
Mattana Francesco ◽  
Calabrò Diletta ◽  
Paccagnella Andrea ◽  
Broccoli Alessandro ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Ct Imaging ◽  
Recent Advances ◽  
Pet Ct

scholarly journals AB1087 DETECTING AXIAL AND PERIPHERAL NEW BONE FORMATION IN SPONDYLOARTHRITIS PATIENTS USING [18F]FLUORIDE PET-CT IMAGING

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1832.2-1833
Author(s):  
J. De Jongh ◽  
R. Hemke ◽  
G. C. J. Zwezerijnen ◽  
M. Yaqub ◽  
I. Van der Horst-Bruinsma ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Bone Formation ◽  
Ct Imaging ◽  
Whole Body ◽  
Therapeutic Effects ◽  
New Bone Formation ◽  
Research Support ◽  
Patella Tendon ◽  
Pet Ct ◽  
18F Fluoride

Background:Bone formation in spondyloarthritis (SpA) is presumably related to local enthesitis/peri-articular inflammation and ultimately may lead to functional limitation (1,2). X-rays only allow long-term monitoring of bone formation (≥2 years) (3). Imaging techniques that can visualize bone formation at an early stage would therefore be valuable. Positron Emission Tomography (PET) using [18F]Fluoride can visualize and quantify (early changes in) bone formation at molecular level (4).Objectives:To investigate the feasibility of [18F]Fluoride to assess new bone formation at axial and peripheral enthesial sites in SpA patients.Methods:Thus far, 5 of the total of 15 patients with clinically active ankylosing spondylitis (AS) (according to modified New York criteria and BASDAI ≥4) and 8 of the 25 patients with active psoriatic arthritis (PsA) (according to CASPAR criteria and ≥1 clinically active enthesitis) were included. Of each patient, a whole body [18F]Fluoride PET-CT scan was performed. All scans were visually judged and scored dichotomously by one reader (blinded for clinical data) for PET-positive lesions in the spine, peripheral enthesis sites and joints. Low dose CT was used for anatomical reference.Results:The study is ongoing, with whole body [18F]Fluoride PET-CT scans available in five AS patients and eight PsA patients. In 4/5 AS scans, at least (≥1) PET positive lesions were found in the cervical, thoracic and/or lumbar vertebrae. These were mainly found in anterior corners of vertebrae and bridging syndesmophytes (Fig. 1A). In all eight PsA patients, at least 1 PET positive lesion was visualized, projected either at the site of a tendon attachment (fascia plantaris, achilles- and patella tendon (Fig 1B)) or peri-articularly (in the ankle or wrist).Fig 1.[18F]Fluoride uptake in the cervical, thoracic and lumbar spine in a clinically active AS patient (A) and in the patella tendon of the right knee in a clinically active PsA patient (B)Conclusion:[18F]Fluoride PET uptake, reflecting new bone formation, can be visualized at heterogeneously distributed enthesis and (peri-)articular sites in AS- and PsA patients. The technique therefore is sensitive to visualize new bone formation and may reflect local disease activity. Additional scans will be collected and analyzed quantitatively, also after anti-TNF or Secukinumab treatment, to further investigate the applicability of [18F]Fluoride PET for monitoring of therapeutic effects on bone formation in SpA.References: :[1]Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948-53.[2]Rezvani A, Bodur H, Ataman S, Kaya T, Bugdayci DS, Demir SE, et al. Correlations among enthesitis, clinical, radiographic and quality of life parameters in patients with ankylosing spondylitis. Mod Rheumatol. 2014;24(4):651-6.[3]Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8..[4]Bruijnen ST, Verweij NJF, van Duivenvoorde L, Bravenboer N, Baeten D, van Denderen JC, et al. [18F]Fluoride PET-CT imaging of bone formation in ankylosing spondylitis before and after 12 weeks of anti-TNF treatment. 2017.Acknowledgments:We thank EULAR Foreum, Pfizer and Novartis for financial support of this investigator initiated study.Disclosure of Interests:Jerney de Jongh: None declared, Robert Hemke: None declared, Gerben C.J. Zwezerijnen: None declared, Maqsood Yaqub: None declared, Irene van der Horst-Bruinsma Grant/research support from: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Consultant of: AbbVie, Novartis, Eli Lilly, Bristol-Myers Squibb, MSD, Pfizer, UCB Pharma, Marleen G.H. van de Sande Grant/research support from: Novartis, Eli lily, UCB, Jansen, Consultant of: Abbvie, Novartis, Eli lily, MSD, Arno Van Kuijk: None declared, Irene Bultink: None declared, Lot Burgemeister: None declared, Nancy M.A. van Dillen: None declared, Alexandre Voskuyl: None declared, Conny J. van der Laken: None declared

Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies

2013 ◽  
Vol 34 (6) ◽  
pp. 540-543 ◽  
Author(s):  
Kuruva Manohar ◽  
Anish Bhattacharya ◽  
Bhagwant R. Mittal
Keyword(s):  
Fdg Pet ◽  
Ct Imaging ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Brain

scholarly journals Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma

2021 ◽  
Author(s):  
Olwen Westerland ◽  
◽  
Ashik Amlani ◽  
Christian Kelly-Morland ◽  
Michal Fraczek ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Data ◽  
Bone Disease ◽  
Fdg Pet ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Bone Lesions ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract Purpose Comparative data on the impact of imaging on management is lacking for multiple myeloma. This study compared the diagnostic performance and impact on management of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and whole-body magnetic resonance imaging (WBMRI) in treatment-naive myeloma. Methods Forty-six patients undergoing 18F-FDG PET/CT and WBMRI were reviewed by a nuclear medicine physician and radiologist, respectively, for the presence of myeloma bone disease. Blinded clinical and imaging data were reviewed by two haematologists in consensus and management recorded following clinical data ± 18F-FDG PET/CT or WBMRI. Bone disease was defined using International Myeloma Working Group (IMWG) criteria and a clinical reference standard. Per-patient sensitivity for lesion detection was established. McNemar test compared management based on clinical assessment ± 18F-FDG PET/CT or WBMRI. Results Sensitivity for bone lesions was 69.6% (32/46) for 18F-FDG PET/CT (54.3% (25/46) for PET component alone) and 91.3% (42/46) for WBMRI. 27/46 (58.7%) of cases were concordant. In 19/46 patients (41.3%) WBMRI detected more focal bone lesions than 18F-FDG PET/CT. Based on clinical data alone, 32/46 (69.6%) patients would have been treated. Addition of 18F-FDG PET/CT to clinical data increased this to 40/46 (87.0%) patients (p = 0.02); and WBMRI to clinical data to 43/46 (93.5%) patients (p = 0.002). The difference in treatment decisions was not statistically significant between 18F-FDG PET/CT and WBMRI (p = 0.08). Conclusion Compared to 18F-FDG PET/CT, WBMRI had a higher per patient sensitivity for bone disease. However, treatment decisions were not statistically different and either modality would be appropriate in initial staging, depending on local availability and expertise.

scholarly journals Leydig cell tumor of the testis: an incidental finding at 18F-FDG PET/CT imaging

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Almalki Yassir
Keyword(s):  
Leydig Cell ◽  
Fdg Pet ◽  
Chronic Rejection ◽  
Ct Imaging ◽  
The Body ◽  
Whole Body ◽  
Pet Ct ◽  
18F Fdg ◽  
The Right ◽  
Fdg Pet Ct

Abstract Background Leydig cell tumors (LCTs) represent the most common form of stromal tumors. We reported the 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) findings of a patient with testicular LCT. Case presentation A 50-year-old man with a history of end-stage renal disease and renal transplantation 19 years ago. One year earlier, he started to have a chronic rejection. During the investigation to determine the cause of chronic rejection, a suspicious lesion in the graft with a collection around it was seen on ultrasound (US) images, raising the possibility of post-transplant lymphoproliferative disorder (PTLD). The patient was referred for further evaluation by whole body 18F-FDG PET/CT imaging. The image finding revealed an incidental hypermetabolic focal lesion in the right testicle—no other specific findings in the remaining parts of the body nor definitive FDG avid lymphadenopathy to suggest PTLD. Testicular US was requested and showed a well-defined right-sided heterogeneous hypoechoic intratesticular focal mass at the upper pole of the right testis with significant internal vascularity on the color Doppler imaging. The patient underwent a right radical orchidectomy, and the tumor was pathologically confirmed as an LCT. Conclusion In our case, 18F-FDG-PET/CT has been helpful in incidentally detecting this rare testicular tumor in a patient with suspected PTLD.

Sign in / Sign up

Export Citation Format

Share Document